Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
New Haven, Connecticut. September 8, 2008 — Rib-X Pharmaceuticals, Inc.,
a development stage company focused on the discovery and development of novel antibiotics for
the treatment of antibiotic resistant infections, announced today the formation of its Clinical
Advisory Board. The Board, comprised of six infectious disease specialists, will provide oversight
and counsel on matters related to the Company's clinical development programs.
Dr. Robert C. Moellering, Jr., M.D., will serve as Chairman of the Clinical Advisory Board. From 1999 to 2005, Dr. Moellering was the Herrman L. Blumgart Professor of Medicine at Harvard Medical School and Chairman of the Department of Medicine at Beth Israel Deaconess Medical Center, Boston. He now holds the Shields Warren-Mallinckrodt Chair of Medical Research at Harvard Medical School, and was the founder and served as the C.E.O. of the Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center until 2004.
Other individuals named to the Advisory Board include:
"This world-class Advisory Board was attracted to the Rib-X mission of discovering and developing new therapies for life-threatening, resistant bacterial infections, and we are proud to have them as colleagues and advisors at this important time in our growth," said Susan Froshauer, Ph.D., President and C.E.O. of Rib-X. "The formation of the Clinical Advisory Board is indicative of our evolution as a Company and we look forward to working with these board members to advance our clinical programs."
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product driven small molecule drug discovery and development company focused on the structure based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community acquired and hospital acquired pathogens. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology, and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotic classes. The Company currently has two programs in human clinical trials, the radezolid (RX-1741) designer oxazolidinone program as an oral/IV agent to treat serious hospital Gram-positive infections and the delafloxacin, (RX-3341) program, a next generation fluoroquinolone, active against a broad spectrum of bacteria, including methicillin resistant Staphylococcus aureus. Additionally, the Company has multiple drug discovery programs. The first of these is an exciting discovery program that is well on its way toward the identification of new chemical classes of antibiotics active against multi-drug resistant Gram-negative bacteria in the hospital. The second of these programs is focused on design and development of an IV and orally active macrolide for treatment of infections in the nursing home and hospital setting, including those caused by MRSA and enterococci. Radezolid and the multiple discovery programs derive from Rib-X's proprietary use of the ribosome structure and computational tools.
Dr. Robert C. Moellering, Jr., M.D., will serve as Chairman of the Clinical Advisory Board. From 1999 to 2005, Dr. Moellering was the Herrman L. Blumgart Professor of Medicine at Harvard Medical School and Chairman of the Department of Medicine at Beth Israel Deaconess Medical Center, Boston. He now holds the Shields Warren-Mallinckrodt Chair of Medical Research at Harvard Medical School, and was the founder and served as the C.E.O. of the Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center until 2004.
Other individuals named to the Advisory Board include:
- Helen W. Boucher, M.D., Assistant Professor of Medicine, Tufts University School of Medicine, Director of the Infectious Diseases Fellowship Program, and Staff Physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, Boston.
- Henry F. Chambers, M.D., Chief Professor of Medicine in the Division of Infectious Diseases at San Francisco General Hospital, and the Director of the University of California, San Francisco Infectious Diseases Fellowship Training Program.
- Barbara E. Murray, M.D., Director of the Division of Infectious Diseases at the University of Texas-Houston Medical School, and Co-Director of the UTHSC-H Center for the Study of Emerging and Re-Emerging Pathogens.
- Leon G. Smith, M.D., Professor of Medicine and Preventive Medicine / Community Health at the University of Medicine and Dentistry of New Jersey, Chair of the Residency Program in Internal Medicine at Seton Hall University School of Graduate Medical Education, and the Director of Medicine and Chief of Infectious Disease at St. Michael's Medical Center.
- Richard P. Wenzel, M.D., M.Sc., Professor and Chairman of the Department of Internal Medicine, Senior Associate Dean for Clinical Affairs, and President of MCV Physicians at the Medical College of Virginia / Virginia Commonwealth University in Richmond, Virginia.
"This world-class Advisory Board was attracted to the Rib-X mission of discovering and developing new therapies for life-threatening, resistant bacterial infections, and we are proud to have them as colleagues and advisors at this important time in our growth," said Susan Froshauer, Ph.D., President and C.E.O. of Rib-X. "The formation of the Clinical Advisory Board is indicative of our evolution as a Company and we look forward to working with these board members to advance our clinical programs."
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product driven small molecule drug discovery and development company focused on the structure based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community acquired and hospital acquired pathogens. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology, and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotic classes. The Company currently has two programs in human clinical trials, the radezolid (RX-1741) designer oxazolidinone program as an oral/IV agent to treat serious hospital Gram-positive infections and the delafloxacin, (RX-3341) program, a next generation fluoroquinolone, active against a broad spectrum of bacteria, including methicillin resistant Staphylococcus aureus. Additionally, the Company has multiple drug discovery programs. The first of these is an exciting discovery program that is well on its way toward the identification of new chemical classes of antibiotics active against multi-drug resistant Gram-negative bacteria in the hospital. The second of these programs is focused on design and development of an IV and orally active macrolide for treatment of infections in the nursing home and hospital setting, including those caused by MRSA and enterococci. Radezolid and the multiple discovery programs derive from Rib-X's proprietary use of the ribosome structure and computational tools.
| Media/Investor Contact Information |
|---|
|
Gina Nugent
The Yates Network 617.460.3579 gina@theyatesnetwork.com |